Cardiorenal syndrome in acute decompensated heart failure

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 12, 2009, Pages 2013-2026

  Sarraf, Mohammad ^a   Masoumi, Amirali ^a   Schrier, Robert W ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; BUMETANIDE; CATECHOLAMINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; DOPAMINE; EPLERENONE; FUROSEMIDE; GLYCERYL TRINITRATE; INOTROPIC AGENT; LEVOSIMENDAN; LOOP DIURETIC AGENT; MILRINONE; MINERALOCORTICOID ANTAGONIST; NESIRITIDE; NEUROHORMONE; NITROPRUSSIDE SODIUM; PLACEBO; SPIRONOLACTONE; TOLVAPTAN; TORASEMIDE; TROPONIN; UNINDEXED DRUG; VASODILATOR AGENT;

ACUTE DECOMPENSATED HEART FAILURE; ACUTE HEART FAILURE; ANEMIA; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CONTINUOUS INFUSION; CORONARY ARTERY DISEASE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; HEART FAILURE; HUMAN; HYPERTENSION; HYPONATREMIA; HYPOTENSION; HYPOTHERMIA; INCIDENCE; KIDNEY DISEASE; KIDNEY FAILURE; LOADING DRUG DOSE; LOW DRUG DOSE; LUNG CONGESTION; METABOLIC DISORDER; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS; QRS COMPLEX; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; RISK MANAGEMENT; SYMPATHETIC REFLEX; ULTRAFILTRATION; UREA NITROGEN BLOOD LEVEL;

ACUTE DISEASE; HEART FAILURE; HUMANS; HYPERALDOSTERONISM; KIDNEY DISEASES; RISK FACTORS;

EID: 73849141245     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.03150509     Document Type: Review

References (100)

1. Rosamond W, Flegal K, Furie K, Go A, Greenlund K, Haase N, Hailpern SM, Ho M, Howard V, Kissela B, Kittner S, Lloyd-Jones D, McDermott M, Meigs J, Moy C, Nichol G, O'Donnell C, Roger V, Sorlie P, Steinberger J, Thom T, Wilson M, Hong Y; American Heart Association Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics-2008 update: A report from the American Heart Association Statistics Subcommittee. Circulation 117: e25-e146, 2008
2. Hillege HL, Girbes AR, de Kam PJ, Boomsma F, de Zeeuw D, Charlesworth A, Hampton JR, van Veldhuisen DJ: Renal function, neurohormonal activation, and survival in patients with chronic heart failure. Circulation 102: 203-210, 2000
3. Shlipak MG, Smith GL, Rathore SS, Massie BM, Krumholz HM: Renal function, digoxin therapy, and heart failure outcomes: Evidence from the digoxin intervention group trial. J Am Soc Nephrol 15: 2195-2203, 2004
4. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327: 685-691, 1992
5. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293-302, 1991
6. Schrier RW: Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol 47: 1-8, 2006
7. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY: Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296-1305, 2004
8. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ: Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 41:47-55, 2003
9. NHLBI Working Group: Cardio-Renal Connections in Heart Failure and Cardiovascular Disease. Available at http://www.nhlbi.nih.gov/meetings/ workshops/cardiorenal-hf-hd.htm. Accessed August 2004
10. Adams KF Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, Berkowitz RL, Galvao M, Horton DP; ADHERE Scientific Advisory Committee and Investigators: Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 149: 209-216, 2005
11. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J; ADHERE Scientific Advisory Committee and Investigators: High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: A report from the ADHERE database. J Card Fail 13: 422-430, 2007
12. Fonarow GC, Abraham WT, Albert NM, Gattis Stough W, Gheorghiade M, Greenberg BH, O'Connor CM, Pieper K, Sun JL, Yancy CW, Young JB; OPTIMIZE-HF Investigators and Hospitals: Influence of a performance-improvement initiative on quality of care for patients hospitalized with heart failure: Results of the organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF). Arch Intern Med 167: 1493-1502, 2007
13. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, Dietz R, Gavazzi A, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, van Gilst WH, Widimsky J, Freemantle N, Eastaugh J, Mason J; Study Group on Diagnosis of the Working Group on Heart Failure of the European Society of Cardiology: The Euro-Heart Failure survey program-A survey on the quality of care among patients with heart failure in Europe. Eur Heart J 24: 442-463, 2003
14. Masoudi FA, Baillie CA, Wang Y, Bradford WD, Steiner JF, Havranek EP, Foody JM, Krumholz HM: The complexity and cost of drug regimens of older patients hospitalized with heart failure in the United States, 1998-2001. Arch Intern Med 165: 2069-2076, 2005
15. Ahmed A, Rich MW, Sanders PW, Perry GJ, Bakris GL, Zile MR, Love TE, Aban IB, Shlipak MG: Chronic kidney disease associated mortality in diastolic versus systolic heart failure: A propensity matched study. Am J Cardiol 99:93-398, 2007
16. Ahmed A, Campbell RC: Epidemiology of chronic kidney disease in heart failure. Heart Fail Clin 4: 387-399, 2008
17. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M; Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) Investigators: Shortterm intravenous milrinone for acute exacerbation of chronic heart failure: A randomized controlled trial. JAMA 287: 1541-1547, 2002
18. Schrier RW. Cardiorenal versus renocardiac syndrome: Is there a difference? Nat Clin Pract Nephrol 3: 637, 2007 19. Henry JP, Gauer OH, Reeves JL: Evidence of the atrial location of receptors influencing urine flow. Circ Res 4:85-90, 1956
19. Linden RJ, Kappagoda CT: Atrial receptors and renal blood flow. In: Atrial Receptors, edited by Linden RJ, Kappagoda CT, Cambridge: Cambridge University Press, 1982, pp 235-239
20. Packer M: Neurohormone interaction and adaptations in congestive heart failure. Circulation 77: 721-730, 1988
21. Schrier RW: Body fluid volume regulation in health and disease: A unifying hypothesis. Ann Intern Med 113: 155-159, 1990
22. Schrier RW: Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (1). N Engl J Med 319:1065-1072, 1988
23. Blankstein R, Bakris GL: Renal hemodynamic changes in heart failure. Heart Fail Clin 4: 411-423, 2008
24. Schrier RW, Abraham WT: Hormones and hemodynamics in heart failure. N Engl J Med 341: 577-578, 1999
25. Weber K: Mechanisms of disease: Aldosterone in chronic heart failure. N Engl J Med 345: 1689-1697, 2001
26. Kramer RS, Mason DT, Braunwald E: Augmented sympathetic neurotransmitter activity in the peripheral vascular bed of patients with congestive heart failure and cardiac norepinephrine depletion. Circulation 38: 629-634, 1968
27. Chidsey CA, Sonnenblick EH, Morrow AG, Braunwald E: Norepinephrine stores and contractile force of papillary muscle from the failing human heart. Circulation 33: 43-51, 1966
28. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819-823, 1984
29. Zeidel ML, Kikeri D, Silva P, Burrowes M, Brenner BM: Atrial natriuretic peptides inhibit conductive sodium uptake by rabbit inner medullary collecting duct cells. JCI 92:1067-1074, 1988
30. Schrier RW, Berl T, Anderson RJ: Osmotic and nonosmotic control of vasopressin release. Am J Physiol 236: F321-F332, 1979
31. Schrier RW: Pathogenesis of sodium and water retention in high-output and low-output cardiac failure, nephrotic syndrome, cirrhosis, and pregnancy (2). N Engl J Med 319:1127-1134, 1988
32. Chen HH, Schrier RW: Pathophysiology of volume overload in acute heart failure syndromes. Am J Med 119 [12 Suppl 1]: S11-S16, 2006
33. Gottlieb Gottlieb SS, Abraham W, Butler J, Forman DE, Loh E, Massie BM, O'Connor CM, Rich MW, Stevenson LW, Young J, Krumholz HM: The prognostic importance of different definitions of worsening renal function in congestive heart failure. Card Fail 8: 136-141, 2002
34. Liang KV, Williams AW, Greene EL, Redfield MM: Acute decompensated heart failure and the cardiorenal syndrome. Crit Care Med 36 [Suppl 1]: S75-S88, 2008
35. Firth JD, Raine AE, Ledingham JG: Raised venous pressure: A direct cause of renal sodium retention in oedema? Lancet 1: 1033-1035, 1988
36. Schrier RW, deWardener HE: Tubular reabsorption of sodium ion: Influence of factors other than aldosterone and glomerular filtration rate. N Engl J Med 285: 1292-1303, 1971
37. Gottlieb SS: Adenosine A1 antagonists and the cardiorenal syndrome. Curr Heart Fail Rep 5: 105-109, 2008
38. Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW; ADHERE Scientific Advisory Committee and Investigators: ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): Developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 112: e154-e235, 2005
39. Fonarow GC, Heywood JT, Heidenreich PA, Lopatin M, Yancy CW; ADHERE Scientific Advisory Committee and Investigators: Temporal trends in clinical characteristics, treatment and outcomes for heart failure hospitalizations, 2002 to 2004: Findings from the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 153: 1021-1028, 2007
40. Shah MR, Hasselblad V, Stevenson LW, Binanay C, O'Connor CM, Sopko G, Califf RM: Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: The ESCAPE trial. JAMA 287: 1541-1547, 2005
41. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ; Candesartan in Heart Failure: Renal function as a predictor of out-come in a broad spectrum of patients with heart failure. CHARM investigators Circ 13: 671-678, 2006
42. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, O'Connor CM, Sun JL, Yancy CW, Young JB: Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: A report from the OPTIMIZE-HF registry. JACC 50: 768-777, 2007
43. Fonarow GC, Adams KF Jr, Abraham WT, Yancy CW, Boscardin WJ; ADHERE Scientific Advisory Committee, Study Group, and Investigators: Risk stratification for inhospital mortality in acutely decompensated heart failure: Classification and regression analysis. JAMA 293: 572-580, 2005
44. Klein L, Massie BM, Leimberger JD, O'Connor CM, Piña IL, Adams Jr KF, Califf RM, Gheorghiade M, for the OPTIME-CHF Investigators: Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival. Results from the Outcomes of a Prospective Trial of Intravenous Milrinonoe for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Cir Heart Fail 1: 25-33, 2008
45. Drazner MH, Rame JE, Stevenson LW, Dries DL: Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure. N Engl J Med 345: 574-581, 2001
46. Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O'Connor CM, She L, Yancy CW, Young J, Fonarow GC; OPTIMIZE-HF Investigators and Coordinators: Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: An analysis from the OPTIMIZE-HF registry. Eur Heart J 28: 980-988, 2007
47. Schrier RW: Blood urea nitrogen and serum creatinine. Not married in heart failure. Cir Heart Fail 1: 2-5, 2008
48. Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I, Nishino K, Yoshimasa T, Nakao K: Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiac hypertrophy: Evidence for BNP as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 96: 1280-1287, 1995
49. Harrison A, Morrison LK, Krishnaswamy P, Kazanegra R, Clopton P, Dao Q, Hlavin P, Maisel AS: B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 39: 131-138, 2002
50. Perna ER, Macín SM, Parras JI, Pantich R, Farías EF, Badaracco JR, Jantus E, Medina F, Brizuela M: Cardiac troponin T levels are associated with poor short- and longterm prognosis in patients with acute cardiogenic pulmonary edema. Am Heart J 143: 814-820, 2002
51. You JJ, Austin PC, Alter DA, Ko DT, Tu JV: Relation between cardiac troponin I and mortality in acute decompensated heart failure. Am H J 153: 462-470, 2007
52. Peacock WF 4th, De Marco T, Fonarow GC, Diercks D, Wynne J, Apple FS, Wu AH; ADHERE Investigators: Cardiac troponin and outcome in acute heart failure. N Engl J Med 358: 2117-2126, 2008
53. Lee WH, Packer M: Prognostic importance of serum sodium concentration and its modification by convertingenzyme inhibition in patients with severe chronic heart failure. Circulation 73: 257-267, 1986
54. Klein L, O'Connor CM, Leimberger JD, Gattis-Stough W, Piña IL, Felker GM, Adams KF Jr, Califf RM, Gheorghiade M; OPTIME-CHF Investigators: Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: Results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIMECHF) study. Circulation 111: 2454-2460, 2005
55. Gheorghiade M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, Piña IL, Fonarow GC, DeMarco T, Pauly DF, Rogers J, DiSalvo TG, Butler J, Hare JM, Francis GS, Stough WG, O'Connor CM: Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE trial. Arch Intern Med 167: 1998-2005, 2007
56. Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C; SALT Investigators: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 355: 2099-2112, 2006. Epub 2006 Nov 14
57. Gheorghiade M, Gattis WA, O'Connor CM, Adams Jr KF, Elkayam U, Alejandro Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Cesare Orlandi C: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA 219: 1963-1971, 2004
58. Konstam MA, Gheorghiade M, Burnett JC Jr., Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA 297: 1319-1331, 2007. Epub 2007 Mar 25
59. Gheorghiade M, Konstam MA, Burnett JC Jr., Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators: Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA 297: 1332-1343, 2007. Epub 2007 Mar 25
60. Fishbane S: Anemia and cardiovascular risk in the patient with kidney disease. Heart Fail Clin 4: 401-410, 2008
61. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, Niebauer J, Hooper J, Volk HD, Coats AJ, Anker SD: Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 102: 3060-3067, 2000
62. Al-Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, Sarnak MJ: Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38: 955-962, 2001
63. Silverberg DS, Wexler D, Sheps D, Blum M, Keren G, Baruch R, Schwartz D, Yachnin T, Steinbruch S, Shapira I, Laniado S, Iaina A: The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: A randomized controlled study. J Am Coll Cardol 37: 1775-1780, 2000
64. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D; CHOIR Investigators: CHOIR Investigators: CHOIR investigators: Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 355:2085-2098, 2006
65. Amgen: RED-HF™ Trial-Reduction of Events with Darbepoetin Alfa in Heart Failure Trial. Available at: http://clinicaltrials.gov/ct/show/ NCT00358215. Accessed November 26, 2007
66. Heywood JT: The cardiorenal syndrome: Lessons from the ADHERE database and treatment options. Heart Fail Rev 9:195-201, 2004
67. Krumholz HM, Chen YT, Vaccarino V, Wang Y, Radford MJ, Bradford WD, Horwitz RI: Correlates and impact on outcomes of worsening renal function in patients > or = 65 years of age with heart failure. Am J Cardiol 85: 1110-1113, 2000
68. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, Stough WG, Yancy CW, Young JB, Fonarow GC; OPTIMIZE-HF Investigators and Coordinators: Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 296: 2217-2226, 2006
69. Forman DE, Butler J, Wang Y, Abraham WT, O'Connor CM, Gottlieb SS, Loh E, Massie BM, Rich MW, Stevenson LW, Young JB, Krumholz HM: Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. Am Coll Cardiol 43:61-67, 2004
70. Wang NC, Maggioni AP, Konstam MA, Zannad F, Krasa HB, Burnett JC Jr, Grinfeld L, Swedberg K, Udelson JE, Cook T, Traver B, Zimmer C, Orlandi C, Gheorghiade M; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators: for the Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators: Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA 299: 2656-2666, 2008
71. McKinley MJ, Albiston AL, Allen AM, Mathai ML, May CN, McAllen RM, Oldfield BJ, Mendelsohn FA, Chai SY: The brain renin-angiotensin system: Location and physiological roles. Int J Biochem Cell Biol 35: 901-918, 2003
72. Brahmajee K, Nallamothu BK, Payvar S, Kosiborod M, Masoudi FA, Havranek EP, Foody JM, Casscells SW, Krumholz HM: Admission body temperature and mortality in elderly patients hospitalized for heart failure. J Am Col Card 47: 2563-2564, 2006
73. Payvar S, Orlandi C, Stough WG, Elkayam U, Ouyang J, Casscells SW, Gheorghiade M; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators: Comparison of 60-day mortality in hospitalized heart failure patients with versus without hypothermia. Am J Card 98: 1485-1488, 2006
74. Cleland JG, Pennel D, Ray S, Murray G, MacFarlane P, Cowley A, Coats A, Lahiri A: The Carvedilol Hibernation Reversible Ischaemia Trial; Marker of Success (CHRISTMAS) Eur J Heart Fail 1: 191-196, 1999
75. Rossi JS, Flaherty JD, Fonarow GC, Nunez E, Stough WG, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, Yancy CW, Young JB, Davidson CJ, Gheorghiade M: Influence of coronary artery disease and coronary revascularization status on outcomes in patients with acute heart failure syndromes: A report from OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure). Eur J Heart Fail 2008 Nov 8. [Epub ahead of print]
76. Adams KF, Lindenfeld J, Arnold JMO, Baker DW, Barnard DH, Baughman KL, Boehmer JP, Deedwania P, Dunbar SB, Elkayam U, Gheorghiade M, Howlett JG, Konstam MA, Kronenberg MW, Massie BM, Mehra MR, Miller AB, Moser DK, Patterson JH, Rodeheffer RJ, Sackner-Bernstein J, Silver MA, Starling RC, Stevenson LW, Wagoner LE: Heart Failure Society of America. HFSA 2006 Comprehensive Heart Failure Guideline. J Card Fail 12: e1-e122, 2006
77. Brater DC: Diuretic therapy. N Engl J Med 339: 387-395, 1998
78. Wang DJ, Gottlieb SS. Diuretics: Still the mainstay of treatment. Crit Care Med 36 [Suppl]: s89-s94, 2008
79. Goodfriend TL, Ball DL, Oelkers W Bähr VW: Torsemide inhibits aldosterone secretion in vitro. Life Sci 63: L45-Ll50, 1998
80. Sica DA: Edema mechanisms in patients with heart failure and treatment options. Heart Failure Clin 4: 511-518, 2008
81. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341: 709, 1999
82. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309, 2003
83. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA: Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351: 543, 2004
84. Pitt B, Bakris G, Ruilope LM, Dicarlo L, Mukherjee R; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators: Serum potassium and clinical outcomes in the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS). Circ 118: 1643-1650, 2008
85. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF): Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: A randomized controlled trial [erratum appears in JAMA 288: 577, 2002[. JAMA 287: 1531-1540, 2002
86. Sackner-Bernstein JD, Skopicki HA, Aaronson KD: Risk of worsening renal function with nesiritide in patient with acutely decompensated heart failure [published erratum in Circulation 111: 2274, 2005]. Circulation 111: 1487-1491, 2005
87. Riter HG, Redfield MM, Burnett JC, Chen HH: Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. J Am Coll Cardiol 47: 2334-2335, 2006
88. Elkayam U, Janmohamed M, Habib M, Hatamizadeh P: Vasodilators I the management of acute heart failure. Cri Care Med 361 [Suppl 1]: S95-S105, 2008
89. Liang CS, Sherman LG, Doherty JU, Wellington K, Lee VW, Hood WB Jr: Sustained improvement of cardiac function in patients with congestive heart failure after shortterm infusion of dobutamine. Circulation 69: 113-119, 1984
90. Dies F, Krell MJ, Whitlow P: Intermittent dobutamine in ambulatory outpatients with chronic cardiac failure [Abstract]. Circulation 74 [Suppl II]: 38, 1986
91. Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH, Cheng ML, Wynne J; ADHERE Scientific Advisory Committee and Investigators; ADHERE Study Group: In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: An analysis from the Acute Decompensated Heart Failure National Registry (ADHERE) J Am Coll Cardiol 46: 57-64, 2005
92. The Digitalis Investigation Group: The effect of digoxin on mortality and morbidity in patients with heart failure (the DIG trial). N Engl J Med 336: 525-533, 1997
93. Metra M, Nodari S, D'Aloia A, Muneretto C, Robertson AD, Bristow MR, Dei Cas L: Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: A randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol and carvedilol. J Am Coll Cardiol 40:1248-1258, 2002
94. Funaya H, Kitakaze M, Node K, Minamino T, Komamura K, Hori M: Plasma adenosine levels increase in patient with chronic heart failure. Criculation 97: 1363-1365, 1997
95. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, Dyer F, Gomez M, Bennett D, Ticho B, Beckman E, Abraham WT: BG9717 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. Circulation 105:1349-1353, 2002
96. Gottlieb SS, Skettino SL, Wolff A, Beckman E, Fisher ML, Freudenberger R, Gladwell T, Marshall J, Cines M, Bennett D, Liittschwager EB: Effect of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure. J Am Coll Cardiol 35: 56-59, 2000
97. Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA; UNLOAD Trial Investigators: Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 49: 675-683, 2007
98. Mebazza A, Nieminen M, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Põder P, Kivikko M; SURVIVE Investigators: Levosimendan vs dobutamine for patients with acute decompensate heart failure: The SURVIVE randomized trial. JAMA 297: 1883 - 1891, 2007
99. Petersen JW, Felker GM: Inotropes in the management of acute heart failure. Crit Care Med 36 [Suppl 1]: S106-S111, 2008
100. Packer M: REVIVE II: Multicenter placebo-controlled trial of levosimendan on clinical status in acutely decompensated heart failure. Circ 112: 3362-3364, 2005